Context: Acquired immunodeficiency Syndrome (AIDS) is caused by Human immunodeficiency virus type 1 (HIV-1). 4-Thiazolidone nulecus is the target pharmacophore which have diverse biological activities including anti HIV activity. Aim: To study binding behavior of thiazolidinone derivatives on four different crystal structures of HIV-1RT. Material and Method: Binding pattern of some thiazolidinone derivatives was gauged by molecular docking studies on four different receptors bearing PDB code 1ZD1, 1RT2, 1KLM, 1FKP of HIV-RT enzyme using V. Life MDS software. Result and Discussion: The studies revealed hydrogen bonds, hydrophobic interaction and pi-pi interactions playing significant role in binding of the molecules to the enzyme. Conclusion: Interactions, binding energy and dock score of molecule 6 was comparable with the standard drugs.
INTRODUCTION
Acquired immunodeficiency Syndrome (AIDS) is caused by Human immunodeficiency virus type 1 (HIV-1) in which in built defence system of body breaks down completely. Drug treatment comprises of a combination of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/ NTRIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and HIV integrase inhibitors. But in spite of the highly active antiretroviral therapy (HAART) complete eradication of retrovirus is still not achieved. 1 In view of the increasing incidence of resistance to current drug regimens and the frequency of adverse events, the development of novel, selective, potent, safe, inexpensive antiviral agents, that are also effective against mutant HIV strains such as Y188C, Y181C, K103N, L1001 remains a high priority for medical research. 4-Thiazolidone derivatives have attracted continuing interest over the years because of their diverse biological activities including anti HIV activity. [3] [4] [5] [6] [7] [8] [9] these derivatives acts on HIV-1 reverse transcriptase (HIV-1 RT) enzyme. RT inhibitors are of two types: nucleoside reverse transcriptase inhibitors (NRTIs), which act as chain terminators to block the elongation of the HIV-1 viral DNA strand, and non-nucleoside reverse transcriptase inhibitors (NNRTIs), which directly inhibit RT enzyme by binding to the allosteric site near the polymerase active site. In this regard, NNRTIs are more specific and less toxic than NRTIs because they do not affect the activity of cellular polymerases. 4-Thiazolidone derivatives inhibits non-nucleoside reverse transcriptase enzyme. The inhibition of RT is considered as one of the most valuable and practicable approaches to suppress virus spreading NRTIs inhibit RT selectively but are considerably toxic to cellular and mitochondrial DNA synthesis.
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In the present work a library of synthesized thiazolidinone based New chemical entities (NCE's) with anti HIV activity were used for pharmacophore optimization by studying their binding behavior with four different crystal structures of HIV-1RT i.e. 1KLM, 1FKP, 1RT2, 2ZD1. The types of interactions, amino acids involved were analyzed along with the docking score and binding energy. This analysis by comparing with the standard existing drugs helped to gauze the structural requirement of the NCE's for effective anti HIV activity.
METHODOLOGY
A library of Thiazolidin-4-one derivatives as anti HIV agents was synthesized, 10, 11, 12 and was used for the docking study Table 1 . The four crystal structures of HIV-1RT i. e. 1KLM, 1FKP, 1RT2, 2ZD1 were obtained from protein data bank (PDB). The docking study was carried out using V-Life Molecular Design Suite (MDS) Software 4.3. Ligand structures were drawn using Chemdraw software and converted to 3D.This was followed by energy optimization using Merck Molecular Force Field (MMFF) method. The protein crystal structures preparation was carried out in two steps, preparation and refinement. After ensuring chemical correctness, hydrogen was added where hydrogen atoms were missing. Water molecules in the crystal structures were deleted. Protein structures were checked for any incomplete, missing residues, crisscross geometry and Ramchandran plot. Incomplete residues were mutated and missing residues were inserted in the loop. Co crystallized ligand was identified and extracted and other unwanted ligands and ions were removed. Exact Cavity and channel were identified based on hydrophobic surface area of residue within cavity, Ramchandran plot and local geometry analysis. The protein was then optimized and minimum energy conformer was generated by MMFF method. The ligands were docked into a specific cavity protein structure using Genetic algorithm(GA) based for rapid flexible docking technique based on the residues of active site. The protein ligand docked complex was optimized and then checked for various interaction of ligand with receptor like hydrogen bonding, hydrophobic bonding and van der Waal's. After docking, each ligand and receptor was merged and their complex was then energetically optimized. The binding affinity was evaluated by the binding free energy, hydrogen bonding interaction, hydrophobic interaction and RMSD values. Minimum dock score is an indication of stable ligand receptor complex. 13, 14, 15, 16 
RESULT AND DISCUSSION
The molecular docking studies were carried out on four crystal structures of RT enzyme (PDB code 1FKP, 1RT2, 2ZD1, 1KLM). The Molecules were ranked on the basis of Docking score and binding energy Table 2 . The molecular basis of interaction with the non nucleoside inhibitory binding pocket of HIV-1RT was analyzed. Table 3 Molecule 1 Molecule 1 showed binding only with 1FKP and 1RT2 receptors. Groups such as =O, S and N (Ring) were bound through hydrogen bonds with amino acids such as GLN182A (2.384Å), ARG172A (2.419Å), ARG172A (1.475Å) respectively. Similarly with 1RT2, S atom was bound to ARG172A (2.006Å).
Molecule 2
Molecule 2 showed binding only with 1FKP binding site using -OCH 3, S (Ring), N (Ring) to bind THR165A (2.558 Å), ARG172A (1.674 Å), ARG172A (2.343 Å) through hydrogen bonds.
Molecule 3
Module 3 showed hydrogen bond binding with GLN161A (2.533 Å), GLY141B (2.103Å), through =O, THR165A (2.523Å
) with S atom and ARG172A (2.258 Å), TYR181A (1.608Å) with -OH group in the binding pocket of 1FKP. It did not show any hydrogen bond interactions with other receptors.
Molecule 4
Module 4 also showed hydrogen bonding only with 1FKP to the THR165A (2.569Å) and ARG172A (2.459 Å) through -OCH 3 and =O atoms respectively.
Molecule 5
Molecule 5 has shown hydrogen bond interactions with three receptors 2ZD1, 1FKP and 1RT2. With 2ZD1, F atom was found to form hydrogen bond with ARG143B (2.139Å). N atom of the thiazolidinone ring has formed hydrogen bond with ARG172A (1.823Å) in 1FKP receptor. With 1 RT2 receptor the S atom of thiazolidinone ring has shown interaction with GLN161A (2.053 Å), GLY141B (2.424Å) and F atom has shown interaction with ARG143B (1.759 Å) and THR131B (1.625Å). Module 6 showed hydrogen bond interactions with 2ZD1, 1FKP and 1RT2 Figure 1 , 2, 3. In 2ZD1 receptor LYS101A (1.705 Å) interacted with hydrogen of -OH group and also with oxygen of -OH group at2.033 Å distance. Sulphur and carbonyl group of thiazolidinone ring interacted with GLN161A (2.501 Å), GLN182A (2.356 Å) respectively in 1FKP receptor cavity. In 1RT2 the oxygen of -OH formed hydrogen bond with GLN91A (2.506 Å)
Molecule 7
Module 7 showed interaction only with 1RT2 receptor via hydrogen bonds between, N atom of thiazolidinone ring with GLY141B (2.206 Å),-OH group with SER134B (2.546 Å) and =O in the ring with GLN161A (2.131 Å). Standard drug Etravirine showed interactions with all the receptors. In 2ZD1 it showed interaction with GLY141B (1.782 Å), ILE180B (1.811 Å) through -CN group and -NH 2 group respectively. In 1KLM again the -CN group showed interaction with SER134B (2.405 Å). In 1RT2 the NH group formed bond with VAL90A (2.403 Å).With 1FKP there were multiple interaction using -NH group with GLU89A (1.841 Å), -NH 2 group with GLY141B (1.313 Å) and -N of the ring formed two hydrogen bonds with GLN161A (2.589 Å) and GLY141B (2.064 Å).Neverapine interacted with 2ZD1 and 1KLM through the ring N atom to GLU138B (2.658 Å), ASN137B (2.491 Å) and ARG174B (2.332 Å) respectively. Rilprivirine drug showed binding with 2ZD1, 1FKP and 1RT2.The interactions were seen between -NH group and PRO140B (2.567 Å) of 2ZD1 and GLY141B (2.504 Å) of 1RT2. Multiple interactions were seen in 1FKP receptor via GLU138B (2.109 Å), ARG172A (1.917 Å) to the -NH group. Both the N atoms in the ring showed interaction with ARG172A (2.004 Å, 2.095 Å), and one N with ILE180A (1.953 Å). Delaviridine drug interacted well with all the four receptors. In 2ZD1 it formed hydrogen bond through the Pyridine nitrogen to GLN182A (1.390 Å), with 1 FKP two hydrogen bonds were noted with -N (Piperazine) and-N (Indole) through their interaction with ARG172A (1.658 Å), ARG172A (1.213Å) respectively. Incase of 1RT2 the amino acids PRO133B (1.395 Å), ILE142B (2.014 Å) were involved in interaction with nitrogen of -NHSO 
CONCLUSION
In the present work molecular docking study was focused on understanding the binding mode of molecules on different crystal structures of HIV-1RT enzyme. The studies have indicated that thiazolidinone ring plays a crucial role for producing biological activity through hydrogen bond interactions in the binding pocket. Amongst the different substituents -OH group has shown the best hydrogen bonding as in Molecule 3, 6, 7 which would probably contribute to the biological activity. Aromatic interactions are observed with TYR 181, an important active residue for binding affinity of the inhibitor. Molecule 6 can be consider as a lead for further studies due to better docking score, more number of hydrogen bonds, minimum binding energy and key interaction with important amino acid residue (TYR 181A) only with 1FKP.
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